La actualidad de Chiesi

-

27/01/2023

-

-

25/01/2023

-

-

01/12/2022

-

-

01/12/2022

-

-

23/11/2022

-

-

21/11/2022

-

-

18/11/2022

-

-

17/11/2022

-

-

15/11/2022

-

-

03/11/2022

-

-

24/10/2022

-

-

21/10/2022

-

-

17/10/2022

-

-

10/10/2022

-

-

29/09/2022

-

-

29/09/2022

-

-

21/09/2022

-

-

20/09/2022

-

-

19/09/2022

-

-

03/08/2022

-

-

20/07/2022

-

-

14/07/2022

-

-

08/07/2022

-

-

23/06/2022

-

-

16/06/2022

-

-

08/06/2022

-

-

04/06/2022

-

-

03/06/2022

-

-

30/05/2022

-

-

25/05/2022

-

-

17/05/2022

-

-

11/05/2022

-

-

11/04/2022

-

-

07/04/2022

-

-

15/03/2022

-

-

09/03/2022

-

-

28/02/2022

-

-

24/02/2022

-

-

14/12/2021

-

-

30/11/2021

-

-

29/11/2021

-

-

26/11/2021

-

-

17/11/2021

-

-

17/11/2021

-

-

15/11/2021

-

-

15/11/2021

-

-

11/11/2021

-

-

26/10/2021

-

-

25/10/2021

-

-

07/10/2021

-

-

22/07/2021

-

-

19/07/2021

-

-

20/05/2021

-

-

14/05/2021

-

-

11/05/2021

-

-

26/03/2021

-

-

25/03/2021

-

-

22/03/2021

-

-

04/02/2021

-

-

17/12/2020

-

-

27/11/2020

-

-

24/11/2020

-

-

24/11/2020

-

-

23/11/2020

-

-

18/11/2020

-

-

18/11/2020

-

-

12/11/2020

-

-

19/10/2020

-

-

30/09/2020

-

-

18/09/2020

-

-

03/07/2020

-

-

17/06/2020

-

The importance of therapeutic adherence in people...

05/05/2020

-

Chiesi España pone en valor los conocimientos de...

30/04/2020

En el marco del Día Nacional de Fibrosis Quística Barcelona, 30 de abril de 2020. Todos los esfuerzos de...

Chiesi colabora junto a profesionales sanitarios...

20/04/2020

-

Pneumology Residents acquire training in advances...

18/02/2020

SEPAR with the sponsorship of Chiesi Spain annually organizes this meeting for third-year residents whose main...

-

30/01/2020

-

NeumoChiesi 2019 reinforces its commitment to...

22/10/2019

Barcelona, October 22, 2019. NeumoChiesi, is consolidated as a reference appointment in the field of pulmonology. This year, the...

Advances in Cystic Fibrosis and Bronchiectasis...

16/09/2019

Alcalá de Henares, September 16, 2019. The life expectancy of people diagnosed with Cystic Fibrosis has improved...

The training of young pneumologists must be...

27/02/2019

Chiesi Spain and SEPAR recreation for third-year residents in which topics are addressed in a dynamic and agile...

-

21/02/2019

-

-

24/05/2018

-

-

26/04/2018

-

-

26/04/2018

-

-

13/04/2018

-

Chiesi Group receives the European Marketing...

04/04/2018

Lamzede® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological...

Chiesi Spain and Richi Entrepreneurs launch the...

22/03/2018

-

-

18/03/2018

-

-

13/03/2018

-

-

07/03/2018

-

-

22/02/2018

-

New study published in The Lancet shows Trimbow®...

12/02/2018

The TRIBUTE study showed superiority of Chiesi’s triple extrafine formulation Trimbow® over Ultibro®...

Chiesi Group receives positive opinion from CHMP...

29/01/2018

Lamzede® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha Mannosidosis, an ultra-rare,...

"Internal entrepreneurs are key to the evolution...

23/01/2018

Thanks to intrapreneurship, the organization's culture can be developed by innovative ideas or projects while increasing...

Chiesi leads the ranking of italian companies...

02/01/2018

The EU Industrial R & D Investment Ranking of the European Commission in 2017 places the Chiesi Group at the top of...

Balanced nutrition helps prevent decompensation...

21/12/2017

-

-

30/11/2017

-

-

30/11/2017

-

-

28/11/2017

-

-

03/11/2017

-

CHIESI ENTERS INTO AN EXCLUSIVE EX-US PARTNERSHIP...

25/10/2017

Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein...

TRIBUTE study shows superiority of Chiesi’s...

07/09/2017

Chiesi completed a long-term clinical study with its extrafine fixed triple combination (Trimbow®) in COPD...

-

07/09/2017

-

-

31/07/2017

-

Chiesi Group receives the European Marketing...

24/07/2017

Chiesi Group receives the European Marketing Authorisation for Trimbow® (ICS/LABA/LAMA) Parma, Italy July...

Chiesi Farmaceutici completes the acquisition of...

23/06/2017

Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate)...

Respiration Day 2017

28/05/2017

The present and future of chronic obstructive pulmonary disease is the focus of the Respiration Day 2017: from the new GOLD...

"Between 10-15% of cases of asthma in adults can...

24/05/2017

This type of asthma has become the most common occupational lung disease in developed countries1 It is due to the...

-

22/05/2017

-

17/05/2017

-

-

08/05/2017

-

Chiesi Group reports an increased turnover in...

26/04/2017

Chiesi Group reports an increased turnover in 2016 and consolidates its global presence Chiesi Group closes...

The Chiesi Group increases its turnover in 2016...

26/04/2017

The Chiesi Group closes 2016 with a turnover of 571 million euros, 7.0% more than in 2015 (+9.6% with a constant exchange...

GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE

20/04/2017

GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE Parma, 20 April 2017 - Chiesi Farmaceutici Spa (“Chiesi”)...

-

04/04/2017

-

-

29/03/2017

-

Published the second issue of the NewsRARE...

13/12/2016

Published the second issue of NewsRARE magazine about Patient Records and Orphan Drugs The NewsRARE...

-

24/11/2016

-

-

16/11/2016

-

-

11/11/2016

-

NeumoChiesi 2016

07/11/2016

Within the framework of the Days of NeumoChiesi 2016 Big Data will revolutionize the research and treatment of chronic...

The Lancet publishes the results of Chiesi...

07/09/2016

At the Congress of the European Respiratory Society (ERS), currently taking place in London The Lancet publishes...

-

31/05/2016

-

-

22/02/2016

-

-

24/12/2015

-

-

30/11/2015

-